Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance.
Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin-resistance. The metabolic effects of IFG-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.
Froesch
E R
ER
Department of Internal Medicine, University Hospital, Zurich, Switzerland.
Bianda
T
T
Hussain
M A
MA
D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood; D011994:Recombinant Proteins / Q000627:therapeutic use; D012636:Secretory Rate
D007328:Insulin; D008074:Lipoproteins; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone